Compare IDEXX Laboratories, Inc. (IDXX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Toyota Motor Corp — how do they compare? IDEXX Laboratories, Inc. trades at $571.63 (market cap $46.22B), while Toyota Motor Corp trades at $188.38 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 4.8× IDEXX Laboratories, Inc.'s market cap, and Toyota Motor Corp pays a 3.3% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TM | |
|---|---|---|
Market Cap | $46.22B | $221.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $248.29 |
52-Week Low | $526.44 | $166.50 |
Enterprise Value | $47.12B | $414.06B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Toyota Motor (TM) trades at $188.97, up 0.1% on the day, with a bullish technical signal from moving averages. The stock presents attractive valuation metrics, including a P/E of 8.53 and P/B of 0.95, trading below book value. Recent quarterly earnings have consistently beaten expectations, though Q1 2026 results missed estimates due to higher costs, as reported by Zacks Investment Research on August 6, 2026. Cash flow trends show volatility, with a net outflow in 2025 but a projected recovery in 2026.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside, but risks include recall costs, China sales weakness, and margin pressure. Institutional sentiment is cautiously optimistic, with no sell ratings among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
